Health
Medicare Drug Plans Can Now Cover Wegovy for Heart Disease
- Major insurers are silent on whether they’ll pay for Wegovy
- Broad Medicare coverage for obesity seen costing trillions
Novo Nordisk A/S Wegovy brand semaglutide medication.
Photographer: George Frey/BloombergThis article is for subscribers only.
Medicare prescription drug programs can now cover Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy for heart disease.
The Centers for Medicare and Medicaid Services said in a statement that it told Medicare prescription drug benefit plans, known as Part D plans, that anti-obesity medications that receive approval for additional uses can be covered for those indications.